Activated T cells play crucial roles in the pathogenesis of autoimmune diseases, including lupus nephritis (LN). The activation of calcineurin/nuclear factor of activated T cells (NFAT) and STAT4 signaling is essential for T cells to perform various effector functions. Here, we identified the growth factor midkine (MK; gene name, Mdk) as a novel regulator in the pathogenesis of 2,6,10,14-tetramethylpentadecane-induced LN via activation of NFAT and IL-12/STAT4 signaling. Wild-type (Mdk+/+) mice showed more severe glomerular injury than MK-deficient (Mdk−/−) mice, as demonstrated by mesangial hypercellularity and matrix expansion, and glomerular capillary loops with immune-complex deposition. Compared with Mdk−/− mice, the frequency of splenic CD69+ T cells and T helper (Th) 1 cells, but not of regulatory T cells, was augmented in Mdk+/+ mice in proportion to LN disease activity, and was accompanied by skewed cytokine production. MK expression was also enhanced in activated CD4+ T cells in vivo and in vitro. MK induced activated CD4+ T cells expressing CD69 through nuclear activation of NFAT transcription and selectively increased in vitro differentiation of naive CD4+ T cells into Th1 cells by promoting IL-12/STAT4 signaling. These results suggest that MK serves an indispensable role in the NFAT-regulated activation of CD4+ T cells and Th1 cell differentiation, eventually leading to the exacerbation of LN.
neuronal death.\textsuperscript{14,15} In a series of prior studies, we generated mice deficient in the \textit{Mdk} gene (\textit{Mdk}\textsuperscript{−/−}) and used them to demonstrate that MK is involved in inflammation through cytokine induction and modulation of the migration of neutrophils and macrophages in arterial restenosis, rheumatoid arthritis, ischemic renal injury, and diabetic nephropathy.\textsuperscript{16–20} Besides their elicitation via chemotactic activity, MK also serves as a negative immune modulator of Tregs in peripheral lymph nodes. Inhibition of MK caused enhanced Treg expansion and subsequently suppressed autoreactive Th1 cell populations, eventually leading to attenuation of the severity of experimental autoimmune encephalomyelitis similar to multiple sclerosis.\textsuperscript{21,22} It is well recognized that IL-2 signaling is essential for the development and function of Tregs, a potent regulator of T-cell subset. Although IL-2 is induced in the development of experimental autoimmune encephalomyelitis, the exacerbation of LN shows a reduction in IL2 transcription with dysfunction of Tregs.\textsuperscript{23,24} The involvement of MK in the molecular mechanism of LN has not yet been elucidated in detail.

We therefore conducted the present study to investigate the role of MK in the pathogenesis of LN. Notably, MK expressed in splenic CD4\textsuperscript{+} T cells positively regulated Treg-independent differentiation into Th1 cells in active LN. To understand these phenomena, a detailed explanation of how the activation and differentiation of T-cell subsets in LN are orchestrated by MK is required. We demonstrated that activation of CD4\textsuperscript{+} T cells accompanies the secretion of MK that is responsible for skewed cytokine production, which, in turn, enhances splenic-activated CD4\textsuperscript{+} T cells expressing CD69 through the induction of NFAT-mediated gene transcription. In this setting, the altered cytokine profile further promotes the expansion and differentiation of Th1 cells through IL-12/STAT4 signaling. The obtained results enabled an understanding of the potent role of MK in the activation of T cells in autoimmune diseases through amplification of a physiological loop.

\section*{Materials and Methods}

\subsection*{Animals and Experimental Design}

\textit{Mdk}\textsuperscript{−/−} mice were generated as described previously.\textsuperscript{25} After backcrossing of \textit{Mdk}\textsuperscript{+/−} mice for 20 generations with 129/SV mice, \textit{Mdk}\textsuperscript{+/−} mice were mated with each other to generate \textit{Mdk}\textsuperscript{+/+} and \textit{Mdk}\textsuperscript{−/−} mice that were used in this study. Experiments were performed with 8- to 12-week-old female mice weighing 20 to 25 g, and mice were housed under controlled environmental conditions and maintained with standard food and water. LN was induced in \textit{Mdk}\textsuperscript{+/+} and \textit{Mdk}\textsuperscript{−/−} mice with an intraperitoneal injection of TMPD (pristane; 2,6,10,14-tetramethylpentadecane; 0.5 mL/mouse) as described previously.\textsuperscript{26} Mice were sacrificed at 6 months after treatment. MRL/lpr female mice were purchased from Japan SLC, Inc. (Shizuoka, Japan) and then were sacrificed at 3 months after birth. Kidneys and the spleen were removed for examination. All of the animal experiments were performed in accordance with the animal experimentation guidelines of Nagoya University School of Medicine.

\subsection*{Histologic Examination}

Kidney tissues were fixed in 10\% formalin, embedded in paraffin, and then cut into 2-\mu m-thick sections. Sections stained with hematoxylin and eosin and periodic acid-Schiff were used for morphometric analysis of the activity indices of human LN as described previously.\textsuperscript{27,28} In brief, the extent of kidney injury was determined by assessing histologic features reflective of LN activity such as endocapillary hypercellularity, leukocyte infiltration, subendothelial hyaline deposits, fibronoid necrosis/karyorrhexis, cellular crescent, and interstitial inflammation. All of the quantifications were performed in a blinded manner by two independent expert nephropathologists (K.M. and W.S.).

Parts of the kidney tissues were snap-frozen in liquid nitrogen. Sections (4 \mu m thick) were cut with a cryostat and fixed with acetone. The sections were stained with rat anti-mouse IgG antibody (Ab) (Life Technologies, Carlsbad, CA), C3 Ab (Abcam, Cambridge, United Kingdom), C1q mouse Ab (Abcam), or CD68 Ab (AbD Serotec, Oxford, United Kingdom), followed by detection with fluorescein isothiocyanate–conjugated rabbit anti-\textit{Ig} \textit{G} Ab (Zymed Laboratories, San Francisco, CA). The sections were stained with anti-CD3 Ab (Abcam) or rat anti-mouse CD4 Ab (Abcam), followed by biotin-conjugated rabbit anti-rat Ab (Nichirei, Tokyo, Japan). Staining was visualized with 3, 3′-diaminobenzidine (Dako, Carpinteria, CA), which produced a brown color. Negative controls involved replacement of the primary Abs with species-matched Abs. Leukocytes positive for CD3, CD4, or CD68 in the glomerulus of all renal regions were counted under a microscope in a blind manner. For electron microscopic analysis, kidneys were fixed in formalin, embedded in epoxy resin, and stained with uranyl acetate and lead citrate.

\subsection*{Biochemical Examination, Autoantibody Analysis, and IL-2 Measurement}

The ratio of albumin to creatinine in urine was measured as described previously.\textsuperscript{29} The hallmark of LN activity were determined using enzyme-linked immunosorbent assay methods, according to the manufacturers’ instructions (IgG1, G2a, and G2b; R&D Systems Inc., Minneapolis, MN; anti–single-stranded DNA Ab and anti–double-stranded DNA Ab, Shibayagi, Gunma, Japan). The IL-2 levels in the supernatant fluid of cultured T splenocytes were measured with an enzyme-linked immunosorbent assay kit (Thermo Fisher Scientific Inc., Waltham, MA).

\subsection*{Flow Cytometric Analysis}

Splenocytes or renal cells were blocked with saturating amounts of anti-CD16/32 Abs (BD Biosciences, San Diego, CA) and were then stained with the following conjugated
Abs: fluorescein isothiocyanate/allophycocyanin (APC) rat anti-mouse CD3e, fluorescein isothiocyanate/APC/phycoerythrin (PE)-cyanine 7 rat anti-mouse CD4, PE rat anti-mouse CD8a, IL-4, IL-17, CD45R/B220, IgM, CD44, and CD25; APC rat anti-mouse interferon (IFN)-γ, CD138, IgD, and CD62L; Alexa Fluor 488 rat anti-mouse FoxP3, and APC/PE-cyanine 7 rat anti-mouse CD69 (BioLegend, San Diego, CA). Cells were acquired with a FACS Canto II flow cytometer (BD Biosciences).

Real-Time PCR

Mouse kidney tissues were snap-frozen in liquid nitrogen for total mRNA isolation as described previously. Real-time PCR analysis was performed with an Applied Biosystems Prism 7500HT sequence detection system, using TaqMan gene expression assays (Applied Biosystems, Foster City, CA). TaqMan probes and primers for tumor necrosis factor-α (Celp2 Mm01336295_m1), IL-1β (Ibβ Mm00434228_m1), IL-6 (Il6 Mm00439665_m1), IFN-γ (Pglyrp2 Mm01348077_m1), monocyte chemotactant protein 1 (Ccl2 Mm00441242_m1), and glyceraldehyde-3-phosphate dehydrogenase (Gadph Mm99999915_m1) were used. Amplification data were analyzed with Applied Biosystems Sequence Detection software version 1.3.1.

Western Blot Analysis

Mouse kidney and spleen tissues were snap-frozen in liquid nitrogen for protein isolation and were then lyzed in a radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology, Dallas, TX). Lymphocytes from in vitro studies were lyzed with the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (ThermoFisher Scientific Inc.). Western blot analysis was performed as described previously. The blots were incubated with goat-anti-mouse MK Ab,32 monoclonal anti-β-actin Ab (Sigma-Aldrich, St. Louis, MO), rabbit-anti-mouse NFAT1 Ab, histone-H3 Ab, glyceraldehyde-3-phosphate dehydrogenase Ab, STAT1 Ab, phospho-STAT1 Ab, STAT4 Ab (all from Cell Signaling Technology, Danvers, MA), and phospho-NFATc2 Ab (Santa Cruz Biotechnology); and mouse monoclonal anti-mouse phospho-STAT4 Ab (Santa Cruz Biotechnology), followed by incubation with peroxidase-conjugated anti-goat IgG, mouse IgG, and rabbit IgG (Jackson Immunoresearch Laboratories, West Grove, PA). The protein signals were visualized with an Amersham Imager 600 (GE Healthcare, Little Chalfont, United Kingdom).

Intracellular Staining and T-Cell Differentiation Assessment

Splenocytes were restimulated for 5 hours with 50 ng/mL phorbol myristate acetate (Sigma-Aldrich) and 1 μg/mL ionomycin (Sigma-Aldrich) along with brefeldin A (BD Biosciences). After surface staining with the indicated Abs, the cells were fixed with Fixation/Permeablization Buffer (BD Biosciences), permeabilized with Perm/Wash Buffer (BD Biosciences), and stained with the following conjugated Abs: APC rat-anti-mouse IFN-γ, PE rat-anti-mouse IL-4, APC rat-anti-mouse IL-17, PE rat-anti-mouse IL-17, AF488 rat-anti-mouse Foxp3 (BD Biosciences). Naïve CD4+CD62L+ T cells were isolated from the spleen as described previously.36 Purified cells were cultured in RPMI 1640 (Sigma-Aldrich), supplemented with 10% fetal bovine serum and 2 mmol/L l-glutamine, and were then activated with anti-CD3 and anti-CD28 Abs (Life Technologies) for 3 days with the following cytokines and neutralizing Abs for the desired polarization: 10 ng/mL IL-12 (R&D Systems) and 10 μg/mL anti-IL-4 (BioLegend) for Th1 cell polarization; 50 ng/mL IL-4, 200 U/mL IL-2 (R&D Systems), and 10 μg/mL anti–IFN-γ (BioLegend) for Th2 cell polarization; 1 ng/mL transforming growth-factor-β, 50 ng/mL IL-6 (R&D Systems), 5 ng/mL IL-23 (BioLegend), 10 μg/mL anti–IFN-γ, and 10 μg/mL anti–IL-4 for Th17 cell polarization; 5 ng/mL transforming growth-factor-β, 200 U/mL IL-2, and 10 μg/mL anti–IFN-γ for Treg cell polarization.

Statistical Analysis

All values are expressed as means ± SEM. Statistical analyses were performed with an unpaired t-test or the nonparametric U test for single comparisons or analysis of variance for multiple comparisons. Post hoc least significant difference tests were performed if the initial analysis of variance was significant. P < 0.05 was considered significant.

Results

MK Deficiency Ameliorates Glomerular Injury in LN

To investigate the role of MK in the pathogenesis of LN, we evaluated the degree of glomerular injury in Mdk+/+ and Mdk−/− mice at 6 months after TMPD treatment. No obvious differences between the two genotypes were found in kidney and body weight or renal function (Table 1). The spleen weight (Table 1) and total numbers of splenocytes (data not shown) tended to be higher in Mdk−/− LN mice than in wild-type mice; No Rx, no TMPD treatment; TMPD, 2,6,10,14-tetramethylpentadecane.

Table 1 General Characteristics of the Mice Analyzed in This Study

<table>
<thead>
<tr>
<th>Mouse type</th>
<th>Bwt, g</th>
<th>Kidney, g</th>
<th>Spleen, g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mdk−/− (TMPD)</td>
<td>29.8 ± 1.9</td>
<td>0.41 ± 0.09</td>
<td>0.39 ± 0.30</td>
</tr>
<tr>
<td>Mdk−/− (TMPD)</td>
<td>26.8 ± 1.4</td>
<td>0.34 ± 0.03</td>
<td>0.18 ± 0.12</td>
</tr>
<tr>
<td>Mdk−/− (No Rx)</td>
<td>32.0 ± 1.5</td>
<td>0.34 ± 0.02</td>
<td>0.11 ± 0.07</td>
</tr>
<tr>
<td>Mdk−/− (No Rx)</td>
<td>28.8 ± 0.9</td>
<td>0.35 ± 0.08</td>
<td>0.08 ± 0.08</td>
</tr>
</tbody>
</table>

Data are expressed as means ± SEM.

Bwt, body weight; Mdk−/−, midkine gene-deficient mice; Mdk+/+, wild-type mice; No Rx, no TMPD treatment; TMPD, 2,6,10,14-tetramethylpentadecane.
Figure 1  Midkine deficiency ameliorates lupus nephritis in vivo.  A: Representative images of PAS- and HE-stained glomeruli at 6 months in wild-type (Mdk+/+) and in midkine-deficient (Mdk−/−) mice.  B: Immunofluorescence staining of mouse IgG, mouse C3, and mouse C1q at 6 months after TMPD injection.  C: Representative electron micrographs of the glomerulus at 6 months in Mdk+/+ and Mdk−/− mice.  Arrow, mesangial immune-complex deposition; arrowhead, subepithelial immune-complex deposition.  D: The lupus nephritis activity index (range, 0–24) at 6 months after TMPD injection.  E: The urine albumin-creatinine (Alb/Cre) ratio at 6 months.  F: Serum IgG1, IgG2a, and IgG2b titers.  G: Serum anti-ssDNA Ab and anti-dsDNA Ab titers at 6 months.  Data are expressed as values for individual mice and median values (D and E) or means ± SEM (F and G).  n = 11 each TMPD treatment (D); n = 6 no Rx (D); n = 6 (E).  *P < 0.05, **P < 0.01. Scale bars: 50 μm (A and B); 2.0 μm (C, left top, right bottom); 1.0 μm (C, right top, left bottom).  Ab, antibody; dsDNA, double-stranded DNA; HE, hematoxylin and eosin; No Rx, no TMPD treatment; PAS, periodic acid-Schiff; ssDNA, single-stranded DNA; TMPD, 2,6,10,14-tetramethylpentadecane.
Infiltrating Inflammatory Cells Are Less Marked in the Glomeruli of Mdk<sup>−/−</sup> Mice Than in Mdk<sup>+/+</sup> Mice

There is growing evidence for the participation of inflammatory cells in LN<sup>1,2</sup> and for the chemotactic activity of MK.<sup>12</sup> To determine which subsets of leukocytes are induced by MK after TMPD treatment, we assessed the recruitment of inflammatory cells to the lupus kidneys. Infiltrating CD3<sup>+</sup>, CD4<sup>+</sup>, and CD68<sup>+</sup> cells were more prominent in the glomeruli of Mdk<sup>+/+</sup> mice than in the glomeruli of Mdk<sup>−/−</sup> mice (Figure 2, A and B). TMPD treatment significantly augmented CD3<sup>+</sup>CD68<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup>, and CD4<sup>+</sup>CD45<sup>+</sup>IFN-γ<sup>+</sup> cells in the lupus kidneys of Mdk<sup>+/+</sup> mice compared with Mdk<sup>−/−</sup> mice, determined by flow cytometric technique (Figure 2, C–G). These data suggest that effector T cells as well as M1 macrophages were higher in the lupus kidney of Mdk<sup>+/+</sup> mice than in Mdk<sup>−/−</sup> mice. In support of these data and consistent with previous reports,<sup>5,26</sup> high expression of inflammation-related molecules, including tumor necrosis factor-α, IL-1β, IL-6, and monococyte chemoattractant protein 1, was observed in lupus Mdk<sup>+/+</sup> kidneys. The expression of these molecules was significantly higher in Mdk<sup>+/+</sup> than in Mdk<sup>−/−</sup> mice (Figure 2H). IFN-γ levels tended to be higher in lupus Mdk<sup>+/+</sup> mice than in Mdk<sup>−/−</sup> mice. No obvious differences between the two genotypes were found in the frequency of CD4<sup>+</sup>CD45<sup>+</sup>IL-17<sup>+</sup> cells (Figure 2G), Tregs, or in the expression of IL-17 (data not shown).

MK Deficiency Suppresses the Activation of Splenic T Lymphocytes in Vivo

In general, T lymphocytes derived from the spleen play an important role in the development of LN.<sup>1,3</sup> We therefore analyzed the expression of the T-cell—activation markers CD69, CD62L, and CD44 in CD4<sup>+</sup> splenocytes in TMPD-induced Mdk<sup>+/+</sup> and Mdk<sup>−/−</sup> mice. Compared with Mdk<sup>−/−</sup> mice, the percentage of splenic CD4<sup>+</sup>CD69<sup>+</sup> and CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup> cells in Mdk<sup>+/+</sup> mice was higher, whereas the percentage of naive CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup> T cells was decreased (Figure 3, A–C). The profiles of activated T lymphocytes in the spleens were compatible with those of the kidneys. A striking increase in MK expression was found in Mdk<sup>+/+</sup> spleens at 6 months after TMPD treatment (Figure 3, D and E). Flow cytometric profiles of CD4<sup>+</sup> and CD8<sup>+</sup> cells did not show any differences between the two genotypes (data not shown). In addition, T-cell development in the thymus was unchanged by the presence of MK (data not shown). Because T-cell subsets show inappropriate tissue homing in SLE,<sup>2,33</sup> the differentiation of Th cell subsets in the lupus spleen was therefore examined. Consistent with the profiles of renal T lymphocytes, the frequency and the number of Th1 cells were significantly enhanced in TMPD-induced Mdk<sup>+/+</sup> splenocytes compared with Mdk<sup>−/−</sup> splenocytes (Figure 2G and Figure 3, F and G). The number but not the frequency of Th17 cells was also increased after TMPD treatment. No significant differences were seen in the frequency and number of Tregs between TMPD-treated Mdk<sup>+/+</sup> and Mdk<sup>−/−</sup> spleens. No obvious differences were observed in the percentage of mature CD138<sup>+</sup>B220<sup>+</sup>, immature IgD<sup>+</sup>IgM<sup>+</sup>B220<sup>+</sup>, and IgD<sup>+</sup>IgM<sup>−</sup>B220<sup>−</sup> B cells between the two genotypes (Figure 3H). The collective data supported the idea that MK induction was associated with the activation of T cells in TMPD-induced LN mice, particularly of Th1 cells, but was not associated with differentiation of Tregs.

MK Promotes NFAT1-Mediated T-Cell Activation and Th1 Cell Differentiation in Splenocytes in Vitro

To further clarify the involvement of MK in the activation and differentiation of T cells, we next assessed MK
Midkine in Lupus Nephritis

Figure 2  Midkine deficiency prevents the infiltration of inflammatory cells into the lupus kidney. A: Immunohistochemical staining of CD3+, CD4+, and immunofluorescence staining of CD68+ cells in the TMPD-induced lupus kidney. B: The numbers of CD3+, CD4+, and CD68+ cells in glomeruli. C: Representative CD69 staining profiles of gated CD3+ T cells in lupus mice assessed using flow cytometry. D: Percentage of renal CD3+CD69+ cells in C. Black columns, Mdk+/+; white columns, Mdk−/−. E: Representative CD69 staining profiles of gated CD4+ T cells in lupus mice. F: Percentages of renal CD4+CD69+ cells in E. G: Percentages of renal CD4+CD45+IFN-γ+ (Th1) and CD4+CD45+IL17+ (Th17) cells in lupus mice. Renal T-cell subsets were determined by the profiles of intracellular cytokine expression, as described in the Materials and Methods. H: The mRNA expression of inflammation-related molecules in lupus kidneys. Data are expressed as values for individual mice and median values (B), percentages of CD3+CD69+ cells (C), or means ± SEM (D, F, and G). n = 8 to 10 (B and G); n = 6 (D and H). **P < 0.01, *P < 0.05. Scale bar = 50 μm (A). c/gcs, count per glomerular cross section; IFN, interferon; MCP, monocyte chemoattractant protein; TMPD, 2,6,10,14-tetramethylpentadecane; TNF, tumor necrosis factor.

induction in activated T cells and the effect of MK on Th1 cell differentiation in vitro, using naive CD4+ T cells from Mdk+/+ or Mdk−/− spleens. Consistent with the profile of MK expression in vivo (Figure 3, D and E), a gradual increase in MK production in the supernatant fluid of cultured CD4+ T lymphocytes from Mdk+/+ mice was observed during their activation mediated by anti-CD3/CD28 Abs (Figure 4A). MK protein expression in the lysate of activated T cells showed a similar profile (data not shown). To determine whether the difference in the frequency of activated T cells between Mdk+/+ and Mdk−/− mice was due to the presence or absence of MK, we next examined the effect of addition of the MK protein to Mdk−/− activated T cells. The frequency of CD4+CD69+ cells in Mdk+/+ splenocytes exposed to anti-CD3/CD28 Abs was higher at 2 days after stimulation compared with Mdk−/− mice.
In Mdk$^{-/-}$ naive CD4$^+$ T cells exposed to anti-CD3/CD28 Abs in the presence of 300 ng/mL MK, the frequency of activated CD4$^+$ CD69$^+$ T cells was similar to that in Mdk$^{+/+}$ or Mdk$^{-/-}$ mice. We further determined whether MK affects the dephosphorylation and translocation of NFAT into the nucleus, which is closely associated with T-cell subset proliferation in SLE. After exposure to anti-CD3/CD28 Abs, nuclear translocation of NFAT was strikingly lower in Mdk$^{-/-}$ splenocytes than with either Mdk$^{+/+}$ splenocytes or Mdk$^{-/-}$ splenocytes treated with recombinant MK protein (Figure 4, D and E). In support of these results, phosphorylation of NFAT in the cytoplasm was prominent in activated Mdk$^{-/-}$ T lymphocytes, whereas supplementation of the cells with recombinant MK protein strikingly inhibited this phenomenon (Figure 4D). IL2 promoter region includes binding elements for NFAT. In proportion to the nuclear activation of NFAT transcription, therefore, IL-2 expression in the supernatant fluid of cultured T lymphocytes was significantly lower in Mdk$^{-/-}$ splenocytes than in

**Figure 3** CD4$^+$ T cells from the spleens of TMPD-induced mice. A: Representative CD69 staining profiles of gated CD4$^+$ T cells in lupus mice. B: Percentages of splenic CD4$^+$ CD69$^+$ cells in A. Black columns, Mdk$^{+/+}$; white columns, Mdk$^{-/-}$. C: Percentage of CD62L$^+$ CD4$^+$ and CD62L$^-$ CD4$^+$ T cells in the spleens of lupus Mdk$^{+/+}$ or Mdk$^{-/-}$ mice. D: MK expression in the spleen at 6 months determined by Western blot analysis. E: The intensities of the MK bands that were normalized to β-actin. Gray columns, Mdk$^{+/+}$ without TMPD treatment; black columns, Mdk$^{+/+}$ with TMPD treatment. F: Percentages of splenic Th1, Th2, Th17, and CD25$^+$ FoxP3$^+$ Tregs in CD4$^+$ T cells from mice treated with TMPD. G: The number of splenic Th1, Th2, Th17, and Tregs. H: Percentages of splenic CD138$^+$, IgD$^+$ IgM$^-$, and IgD$^+$ IgM$^+$ cells of B220$^+$ cells in lupus splenocytes. Data are expressed as percentages of CD4$^+$ CD69$^+$ cells (A) or means ± SEM (B). n = 6 (B and E); n = 6 to 8 (C and F). *P < 0.05, **P < 0.01. MK, midkine; No Rx, no TMPD treatment; TMPD, 2,6,10,14-tetramethylpentadecane; Treg, regulatory T cell.
**Midkine in Lupus Nephritis**

MK deficiency suppresses the NFAT-mediated activation of splenic T lymphocytes treated with anti-CD3/CD28 antibodies in vitro. A: Western blot analysis of MK induction in the supernatant fluid of cultured Mdk+/+ CD4+ T cells stimulated by anti-CD3/CD28 Abs. B: Representative CD69 staining profile of gated CD4+ T cells in isolated Mdk+/+ splenocytes with/without rhMK after exposure to anti-CD3/CD28 Abs for 2 days. C: Percentage of CD4+CD69+ T cells in isolated CD4+ T cells treated with/without rhMK, as described in panel B. Black columns, Mdk+/+; white columns, Mdk+/--; gray columns, Mdk−/− with rhMK. D: Western blot analysis of nuclear NFAT1 and cytoplasmic phospho-NFATc2 expression in activated T splenocytes. E: The intensity of nuclear NFAT1 bands was normalized as to Histone H3. F: ELISA analysis of IL-2 expression in the supernatant fluid of cultured CD4+ T cells after exposure to anti-CD3/CD28 Abs at 2 days. Data are expressed as percentages of CD4+CD69+ cells (B) or means ± SEM (C). n = 6 to 10 independent experiments (C); n = 6 independent experiments (E and F). *P < 0.05, **P < 0.01. Ab, antibody; ELISA, enzyme-linked immunosorbent assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MK, midkine; NFAT, nuclear factor of activation of T cells; p-, phosphorylated rhMK, recombinant midkine.

*Mdk+/+* splenocytes and *Mdk−/−* splenocytes treated with recombinant MK protein (Figure 4F). MK did not affect Cn expression during T-cell activation (data not shown). These data suggest that MK induced activated CD4+ T cells expressing CD69 through the nuclear activation of NFAT transcription, leading to the promotion of IL-2–associated Th1 cell differentiation.

The molecular network of Th1 cell differentiation involves various essential transcriptional factors, including members of the STAT family induced by various key cytokines. Under conditions of Th1 cell differentiation, the frequency of Th1 cells derived from naïve CD4+ T cells of *Mdk+/+* spleens was significantly higher than that of Th1 cells derived from naïve CD4+ T cells of *Mdk−/−* spleens (Figure 5, A and B). Treatment of *Mdk−/−* naïve CD4+ T cells with the MK protein promoted Th1 cell differentiation, resulting in a Th1 profile similar to that found in *Mdk+/+* cells. In contrast, other T-cell subsets such as Th2 and Th17 cells and Tregs were not affected by the presence or absence of the MK protein in the mice under their respective differentiation conditions (data not shown). STAT1 and STAT4 are required for Th1 cell differentiation derived from naïve T cells in response to 100 ng/mL IFN-γ or 10 ng/mL IL-12, respectively. We therefore examined the function of MK in the activation of STAT1 and STAT4 in this network. No obvious difference between the two genotypes in response to IFN-γ was found in phosphorylation of STAT1 (Figure 5, C and D). Because STAT1 is required for the production of IgG autoantibodies in the pristine-induced mouse model,34 this may cause no significant differences in the titers of IgG subtypes between the two genotypes. In contrast, treatment with IL-12 for Th1 cell polarization promoted STAT4 phosphorylation in *Mdk+/+* T cells to a significantly higher degree than in *Mdk−/−* T cells (Figure 5, E and F). The combined data indicated that MK was induced in activated T cells and participated in Th1 cell differentiation as an amplifying factor via promotion of the IL-12/STAT4 signaling (Figure 6).

**Discussion**

Activated T cells play critical roles in adaptive immune responses in diverse organs, which are categorized by the cytokines they produce.3,35 Various genetic approaches
have been applied to demonstrate the importance of the NFAT signaling pathway in the regulation of T-cell proliferation and the essential role of members of the STAT family in Th cell differentiation. The present study demonstrated that MK derived from CD4+ T cells activates T splenocytes themselves and Th1 cell differentiation, consequently leading to the exacerbation of glomerular nephritis in SLE. Spontaneous lupus-prone MRL/lpr mice also showed MK induction in the kidneys and spleens (Supplemental Figure S1). MK induction in T cells was indeed found during activation of the T cells in vitro, and supplementation of Mdk+/- activated T cells with the MK protein induced the activation of NFAT signaling and CD69 expression in these cells with a profile similar to that in Mdk+/+ activated T cells (Figure 6A). In addition, MK selectively regulates population and differentiation into Th1 cells through IL-12/STAT4 signaling, which is independent of the Treg population (Figure 6B). Therefore, MK may be involved in a physiological loop that acts as an inducer for expansion of activated T cells, including Th1 cells, in LN.

Along with an enhanced and accelerated early T-cell response, activated splenic CD4+ or CD4+CD8- T cells directly invade organ tissues, including the kidneys, which provides aberrant help to B cells to induce various pathogenic autoantibodies. The existence of an impaired fine balance between lymphocyte survival and proliferation and altered cytokine production are considered to be responsible for the pathogenesis of LN. In addition to the infiltration of macrophages into injured kidneys, MK indeed enhances the migration of splenic activated CD4+ T cells in LN through the induction of various chemokines and consequently contributes to augmentation of the severity of LN. In SLE T lymphocytes, NFAT plays a central role, not only in lymphocyte tolerance but also in productive activation of
lymphocytes. On enlargement of the T-cell receptor, the translocates into the nucleus where it exerts crucial transcriptional activity to activate downstream targets in the pathogenesis of SLE. In this setting, NFAT also regulates transcription of the polarizing cytokines IFN-γ and IL-2 that drive Th1 cell differentiation. In the present study, MK deficiency hampered NFAT nuclear translocation, whereas splenic MK induction facilitated the transcriptional activity of NFAT with the production of various immunomodulatory cytokines. In LN representing a variety of aspects and types was found irrespective of enhanced Th1 cell differentiation in Mdk−/− LN mice. As demonstrated in studies of Suzumura and colleagues, MK might regulate the development of Tregs in an IL-2–dependent manner. Because exacerbation of LN shows a striking reduction in IL-2 transcription, MK might not affect Treg population and the subsequent Th17 populations in the present study. In general, Th1 cell differentiation in LN is accompanied by IFN-γ/STAT1 and IL-12/STAT4 signaling. Consequently, MK selectively phosphorylated IL-12/STAT4 signaling to promote Th1 cell differentiation but not phosphorylated IFN-γ/STAT1 signaling. Many basic and clinical studies to date have demonstrated that IFN-γ/STAT1 activation is also required for the pathogenesis of LN. Given these facts, diverse mechanism of LN involves inappropriate tissue homing of T lymphocytes, including Th1, Th17, and Tregs, through the dysfunction of STAT family signaling. The association of variations in the STAT4 gene in LN with severe renal insufficiency has been demonstrated. Although a STAT4-specific blockade ameliorates LN disease activity in MRL/lpr mice with advanced nephritis, transgenic STAT4 knockout mice showed more severe nephritis. Knockout of STAT4 may cause either incomplete STAT inhibition or complementary activation of another pathway in the absence of STAT4 signaling. Therefore, direct or complete suppression of STAT4 signaling makes it difficult to design a therapeutic strategy without side effects. In addition, MK has also been demonstrated to serve as a regulator of mature B-cell survival in B-cell lymphoma. In the present study, Mdk−/− mice did not show any immune-complex deposition in subepithelial areas, which was previously reported. MK may affect humoral immunity through activation of T cells in TMPD-induced LN. Thus, MK may mediate STAT4–associated differentiation of Th1 cells in the pathogenesis of LN, but it may not affect Tregs.

Besides the critical roles of MK in chemotactic activity and subsequent inflammation, MK is also involved in immunologic responses in autoimmune diseases. MK suppresses IL-2–regulated STAT5 phosphorylation and dendritic cell–mediated CD4+CD25+FoxP3+ T cells (Tregs) through the up-regulation of SH2 domain-containing protein tyrosine phosphatase, leading to the exacerbation of experimental autoimmune encephalomyelitis. Inhibition of SH2 domain-containing protein tyrosine phosphatase reduces the proliferation of CD4+CD8+ T cells and decreases the production of IFN-γ and IL-17A in lupus-prone MRL/lpr mice. In the present study, MK did not affect numbers of CD4+CD8+ T cells and the production of these cytokines. Dysfunction of Tregs leads to the exacerbation of LN, with a reduction in IL-2 transcription in TMPD-induced LN and in lupus-prone MRL/lpr mice. Patients with SLE also show suppression of Tregs and a negative correlation between Tregs and disease activity. In addition, Amariyo et al demonstrate that IL-17 plays an important role for the development of TMPD-induced LN. We therefore determined the involvement of Tregs and Th17 cells in mice with TMPD-induced LN in the present study. Of note, however, no obvious difference in the populations of Tregs and Th17 cells between the two genotypes was found irrespective of enhanced Th1 cell differentiation in Mdk−/− LN mice. As demonstrated in studies of Suzumura and colleagues, MK might regulate the development of Tregs in an IL-2–dependent manner. Because exacerbation of LN shows a striking reduction in IL-2 transcription, MK might not affect Treg population and the subsequent Th17 populations in the present study. In general, Th1 cell differentiation in LN is accompanied by IFN-γ/STAT1 and IL-12/STAT4 signaling. Consequently, MK selectively phosphorylated IL-12/STAT4 signaling to promote Th1 cell differentiation but not phosphorylated IFN-γ/STAT1 signaling. Many basic and clinical studies to date have demonstrated that IFN-γ/STAT1 activation is also required for the pathogenesis of LN. Given these facts, diverse mechanism of LN involves inappropriate tissue homing of T lymphocytes, including Th1, Th17, and Tregs, through the dysfunction of STAT family signaling. The association of variations in the STAT4 gene in LN with severe renal insufficiency has been demonstrated. Although a STAT4-specific blockade ameliorates LN disease activity in MRL/lpr mice with advanced nephritis, transgenic STAT4 knockout mice showed more severe nephritis. Knockout of STAT4 may cause either incomplete STAT inhibition or complementary activation of another pathway in the absence of STAT4 signaling. Therefore, direct or complete suppression of STAT4 signaling makes it difficult to design a therapeutic strategy without side effects. In addition, MK has also been demonstrated to serve as a regulator of mature B-cell survival in B-cell lymphoma. In the present study, Mdk−/− mice did not show any immune-complex deposition in subepithelial areas, which was previously reported. MK may affect humoral immunity through activation of T cells in TMPD-induced LN. Thus, MK may mediate STAT4–associated differentiation of Th1 cells in the pathogenesis of LN, but it may not affect Tregs.

The American Journal of Pathology – ajp.amjpathol.org

Midkine in Lupus Nephritis

Figure 6  Schematic diagram that shows the possible contribution of midkine (MK) to lupus nephritis. A: MK-induced T-cell expansion through activation of NFAT. B: MK-regulated differentiation of Th1 cells via the IL-12/STAT4 signaling in lupus nephritis. APC, antigen-presenting cell; Cn, calcineurin; IFN, interferon; NFAT, nuclear factor of activated T cells; TCR, T-cell receptor.
To the best of our knowledge, a hyperactive Cn-NFAT pathway plays an essential role in such signaling for LN. Indeed, the Cn inhibitors, FK506 tacrolimus and cyclosporine A, are highly effective in blocking this signaling in SLE T cells. However, this therapeutic strategy has several side effects, including hypertension, hyperglycemia, and renal toxicity. To date, MK blockade has been shown to improve hypertension in ischemic renal injury through regulation of the renin-angiotensin system.31,32 Accordingly, an MK-regulated device may lead to a reduction in toxicity from LN therapy. Herein, to our knowledge, we demonstrated for the first time that MK induces NFAT-regulated activation of T cells and Th1 cell differentiation through IL-12/STAT4 signaling, leading to the exacerbation of LN (Figure 6). This study of MK thus provides novel insights into LN that may open new avenues and facilitate research on the cause and the development of therapeutics for LN.

Acknowledgments

We thank Noriyuki Suzuki, Naoko Asano, and Yuriko Sawa for their excellent technical assistance and Hitomi Aoyama for secretarial assistance.

Supplemental Data

Supplemental material for this article can be found at http://dx.doi.org/10.1016/j.ajpath.2016.12.006.

References


